Optimapharm
ActiveSummary
Optimapharm has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €96,701 and a net result of €92,091. Equity has been growing by about 61% per year since 2018. Its solvency ranks better than 34% of 3,032 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 17-08-2015 Normal situation
- Activity
- Medical imaging and medical laboratories NACE 86910and 5 others
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 2025
- Establishment unit
- 2.245.331.947 9220 Hamme (Vl.), since 24-08-2015
- Financial year end
- 31 December
- Peppol
- Reachable
Board and ownership
Board
- WALLER IvanaDirector · since 27-04-2023
- Mirna Šenjug NovakDirector · since 23-11-2023
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
Annual accounts 2025
- Gross margin
- €386,186
- ▲ 56.1%
- Turnover
- ≈ €690,000
- estimated
- Profit
- €92,091
- ▲ 756%
- Equity
- €96,701
- ▲ 21×
- Total assets
- €249,302
- ▲ 145%
- Employees on 31-12-2025
- 1
- =
Score breakdownlowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 1.59, cash €40,320Figures for financial year 2025 (filed on 03-06-2026)Equity €96,701 (38.8% of total assets)Show the evidence
Checked score
Score 2025
94
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 55% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency
64+34
equity 38.8% of total assets
Liquidity
38+19
short-term debt 61.2% · cash 16.2%
Profitability
100+18
return on assets 36.9%
Bankruptcy probability within 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.2%● unchanged vs 12-2024
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.3%▲ +0.1 percentage points vs 06-2025highest value
08-2025: 0.1%▼ -0.2 percentage points vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: < 0.1%▼ -0.1 percentage points vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Credit of up to €9,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.59 (1.05 in 2024), above the usual 1.5. Short-term debt is 61.2% and cash 16.2% of total assets. However, 61.2% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 32% of them on solvency, 9% on liquidity, 80% on profitability and 99% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-06-2026, 58 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
58 days early
2024
29 days early
2023
30 days early
2022
28 days early
2021
32 days early
2020
24 days early
2019
2 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 29 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 2 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 03-06-2026 PDF all 10 filings
Amounts without an identifiable currency are taken as euros.
Turnover
≈ €690,000
Estimated: probably between €480,000 and €1.2m
Total assets
€249,302▲ 145%
2024 · €101,946
Net result
€92,091▲ 756%
2024 · €10,759
Working capital
€90,331▲ 20×
2024 · €4,610
Multi-year overview
2018 to 2025, 8 financial yearsOperating result
€126,444
▲ 720%
2025
20182025
Net result
€92,091
▲ 756%
2025
middle half of the sector
20182025
Equity
€96,701
▲ 21×
2025
middle half of the sector
20182025
Total assets
€249,302
▲ 145%
2025
lowest quarter of the sector
20182025
Debt
€152,601
▲ 56.8%
2025
20182025
Working capital
€90,331
▲ 20×
2025
middle half of the sector
20182025
Solvency
38.8%
▲ 34.3pp
2025
middle half of the sector
20182025
Current ratio
1.59
▲ 0.54
2025
middle half of the sector
20182025
Return on assets (ROA)
36.9%
▲ 26.4pp
2025
highest quarter of the sector
20182025
Staff (FTE)
1
=
2025
middle half of the sector
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€13,760--€113,951€40,442€43,449▲ 7.4%€6,934▼ 84.0%€34,053▲ 391%€15,418▼ 54.7%€126,444▲ 720%
Net result€3,944--€120,341€31,076within the sector's middle half€34,838within the sector's middle half▲ 12.1%€2,639below the sector's middle half▼ 92.4%€25,262below the sector's middle half▲ 857%€10,759below the sector's middle half▼ 57.4%€92,091within the sector's middle half▲ 756%
Equity€20,378--€99,964-€68,888below the sector's middle half▲ 31.1%-€34,050below the sector's middle half▲ 50.6%-€31,411below the sector's middle half▲ 7.7%-€6,149below the sector's middle half▲ 80.4%€4,610below the sector's middle half€96,701within the sector's middle half▲ 21×
Total assets€201,749-€63,734▼ 68.4%€158,190below the sector's middle half▲ 148%€165,338below the sector's middle half▲ 4.5%€146,991below the sector's middle half▼ 11.1%€92,342below the sector's middle half▼ 37.2%€101,946below the sector's middle half▲ 10.4%€249,302below the sector's middle half▲ 145%
Debt€181,371-€163,698▼ 9.7%€227,077▲ 38.7%€199,388▼ 12.2%€178,403▼ 10.5%€98,491▼ 44.8%€97,335▼ 1.2%€152,601▲ 56.8%
Working capital€20,078--€100,264-€69,188below the sector's middle half▲ 31.0%-€35,223below the sector's middle half▲ 49.1%-€32,075below the sector's middle half▲ 8.9%-€6,304below the sector's middle half▲ 80.3%€4,610below the sector's middle half€90,331within the sector's middle half▲ 20×
Solvency10.1%--156.8%▼ 166.9pp-43.5%below the sector's middle half▲ 113.3pp-20.6%below the sector's middle half▲ 23.0pp-21.4%below the sector's middle half▼ 0.8pp-6.7%below the sector's middle half▲ 14.7pp4.5%below the sector's middle half▲ 11.2pp38.8%within the sector's middle half▲ 34.3pp
Current ratio1.11-0.39▼ 0.720.70below the sector's middle half▲ 0.310.82below the sector's middle half▲ 0.130.82below the sector's middle half=0.94below the sector's middle half▲ 0.121.05below the sector's middle half▲ 0.111.59within the sector's middle half▲ 0.54
Return on assets (ROA)2.0%--188.8%▼ 190.8pp19.6%above the sector's middle half▲ 208.5pp21.1%above the sector's middle half▲ 1.4pp1.8%below the sector's middle half▼ 19.3pp27.4%above the sector's middle half▲ 25.6pp10.6%within the sector's middle half▼ 16.8pp36.9%above the sector's middle half▲ 26.4pp
Staff (FTE)1.5-1.2▼ 20.0%1.8within the sector's middle half▲ 50.0%1.7within the sector's middle half▼ 5.6%0.2below the sector's middle half▼ 88.2%0.8within the sector's middle half▲ 300%1within the sector's middle half▲ 25.0%1within the sector's middle half=
above
within
below
The sector band is the middle half of the companies in Human health activities (NACE 86). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 8.2 times that of 2024 and the highest since 2021. It is a recovery after the fall in 2024.
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €249,302
Fixed assets
€6,371
Current assets
€242,932
Equity and liabilities €249,302
Equity
€96,701 ▲ 21×
Debt
€152,601 ▲ 56.8%
Debt's share of the balance-sheet total falls from 95.5% to 61.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€128,410▲
2024 · €15,573
Cash flow
€94,056▲
2024 · €10,914
Debt to equity
1.58▼
2024 · 21.11
ROE
95.2%▼
2024 · 233.4%
Interest coverage
over 100▲
2024 · 38.07
Debt ≤ 1 year
€152,601▲
2024 · €97,335
Income taxes
€33,646▲
2024 · €4,250
Staff costs
€257,158▲
2024 · €231,161
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 31-12-2021 | 31-12-2022 | 31-12-2023 | 31-12-2024 | 31-12-2025 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 1 | - | 1 | 1 | 1 |
| full-time | 1 | - | 1 | 1 | 1 |
| in full-time equivalents | 1 | - | 1 | 1 | 1 |
| Average over the year, in full-time equivalents | 1.7 | 0.2 | 0.8 | 1 | 1 |
| On a permanent contract | 1 | - | 1 | 1 | 1 |
| Joined | 0 | 0 | 1 | - | - |
| Left | 1 | 1 | 0 | - | - |
Source: social balance sheet in the 2021 to 2025 annual accounts
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €1,528 | - | - | - | €8,336 |
| Depreciation and write-downs of the year | €354 | €509 | €509 | €155 | €1,965 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | - | €288,860 | €26,705 | €178,889 | €231,161 | €257,158 | ▲ 11.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0 | €0 | €0 | €354 | €509 | €509 | €155 | €1,965 | ▲ 13× |
| Other operating charges640/8 | - | - | - | €514 | €469 | €566 | €603 | €619 | ▲ 2.7% |
| Gross operating margin9900 | €252,522 | €130,148 | €376,163 | €333,176 | €34,618 | €214,017 | €247,337 | €386,186 | ▲ 56.1% |
| Operating profit (loss)9901 | €13,760 | -€113,951 | €40,442 | €43,449 | €6,934 | €34,053 | €15,418 | €126,444 | ▲ 720% |
| Financial income75/76B | - | - | - | - | - | - | €0 | €342 | ▲ 1,037× |
| Recurring financial income75 | €0 | €113 | €0 | - | - | - | €0 | €342 | ▲ 1,037× |
| Financial charges65/66B | - | - | - | €7,913 | €4,305 | €7,926 | €409 | €1,050 | ▲ 157% |
| Recurring financial charges65 | €4,544 | €5,463 | €7,938 | €7,913 | €4,305 | €7,926 | €409 | €1,050 | ▲ 157% |
| Profit (loss) for the period before taxes9903 | €9,217 | -€119,302 | €32,504 | €35,535 | €2,630 | €26,127 | €15,009 | €125,736 | ▲ 738% |
| Income taxes67/77 | €5,273 | €1,039 | €1,428 | €697 | -€9 | €865 | €4,250 | €33,646 | ▲ 692% |
| Profit (loss) for the period9904 | €3,944 | -€120,341 | €31,076 | €34,838 | €2,639 | €25,262 | €10,759 | €92,091 | ▲ 756% |
| Profit (loss) for the period to be appropriated9905 | €3,944 | -€120,341 | €31,076 | €34,838 | €2,639 | €25,262 | €10,759 | €92,091 | ▲ 756% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €201,749 | €63,734 | €158,190 | €165,338 | €146,991 | €92,342 | €101,946 | €249,302 | ▲ 145% |
| Formation expenses20 | €0 | €0 | €0 | - | - | - | - | - | - |
| Fixed assets21/28 | €300 | €300 | €300 | €1,174 | €664 | €155 | - | €6,371 | - |
| Intangible fixed assets21 | €0 | €0 | €0 | - | - | - | - | - | - |
| Tangible fixed assets22/27 | - | - | - | €1,174 | €664 | €155 | - | €6,371 | - |
| Furniture and vehicles24 | - | - | - | €1,174 | €664 | €155 | - | €6,371 | - |
| Financial fixed assets28 | €300 | €300 | €300 | - | - | - | - | - | - |
| Current assets29/58 | €201,449 | €63,434 | €157,890 | €164,165 | €146,327 | €92,187 | €101,946 | €242,932 | ▲ 138% |
| Stocks and contracts in progress3 | €0 | €0 | €0 | - | - | - | - | - | - |
| Amounts receivable within one year40/41 | €192,891 | €51,965 | €141,579 | €148,555 | €129,356 | €65,981 | €86,140 | €202,004 | ▲ 135% |
| Trade receivables40 | - | - | - | €129,333 | €122,661 | €60,442 | €76,153 | €196,983 | ▲ 159% |
| Other amounts receivable41 | - | - | - | €19,222 | €6,695 | €5,538 | €9,987 | €5,021 | ▼ 49.7% |
| Current investments50/53 | €0 | €0 | €0 | - | - | - | - | - | - |
| Cash at bank and in hand54/58 | €6,866 | €10,110 | €14,751 | €14,904 | €16,409 | €26,206 | €15,806 | €40,320 | ▲ 155% |
| Deferred charges and accrued income490/1 | - | - | - | €705 | €562 | - | - | €608 | - |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €201,749 | €63,734 | €158,190 | €165,338 | €146,991 | €92,342 | €101,946 | €249,302 | ▲ 145% |
| Equity10/15 | €20,378 | -€99,964 | -€68,888 | -€34,050 | -€31,411 | -€6,149 | €4,610 | €96,701 | ▲ 21× |
| Contributions10/11 | €18,600 | €18,600 | - | €18,600 | €18,600 | €18,600 | €18,600 | €18,600 | = |
| Reserves13 | €89 | €89 | €89 | €89 | €89 | - | - | - | - |
| Non-distributable reserves130/1 | - | - | - | €89 | €89 | - | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €89 | €89 | - | - | - | - |
| Profit (loss) carried forward14 | €1,689 | -€118,653 | -€87,577 | -€52,739 | -€50,100 | -€24,749 | -€13,990 | €78,101 | - |
| Amounts payable17/49 | €181,371 | €163,698 | €227,077 | €199,388 | €178,403 | €98,491 | €97,335 | €152,601 | ▲ 56.8% |
| Amounts payable within one year42/48 | €181,371 | €163,698 | €227,077 | €199,388 | €178,403 | €98,491 | €97,335 | €152,601 | ▲ 56.8% |
| Trade debts44 | €53,933 | €5,575 | €9,447 | €9,888 | €537 | €14,661 | €1,653 | €16,524 | ▲ 900% |
| Suppliers440/4 | - | - | - | €9,888 | €537 | €14,661 | €1,653 | €16,524 | ▲ 900% |
| Taxes, remuneration and social security45 | - | - | - | €15,484 | - | €49,418 | €48,148 | €88,692 | ▲ 84.2% |
| Taxes450/3 | - | - | - | €2,095 | - | €865 | €865 | €42,248 | ▲ 49× |
| Remuneration and social security454/9 | - | - | - | €13,389 | - | €48,553 | €47,283 | €46,444 | ▼ 1.8% |
| Other amounts payable47/48 | - | - | - | €174,016 | €177,866 | €34,411 | €47,534 | €47,384 | ▼ 0.3% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €3,944 | -€120,341 | €31,076 | €34,838 | €2,639 | €25,262 | €10,759 | €92,091 | ▲ 756% |
| + Depreciation and write-downs630 | €0 | €0 | €0 | €354 | €509 | €509 | €155 | €1,965 | ▲ 13× |
| Operating cash flow (approximation) | €3,944 | -€120,341 | €31,076 | €35,193 | €3,148 | €25,771 | €10,914 | €94,056 | ▲ 762% |
| Investment in fixed assets (approximation) | - | €0 | €0 | -€1,228 | €0 | €0 | - | - | - |
| Change in cash | - | €3,244 | €4,641 | €153 | €1,505 | €9,797 | -€10,400 | €24,514 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 34,693 companies had the same profile as Optimapharm has now. Two years later, 95.3% were still going and 0.7% had gone bankrupt.
- Micro
- 10 to 20 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
95.3%
was still going
3.9%
stopped otherwise
0.7%
went bankrupt
That fits the bankruptcy probability of Optimapharm itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for Optimapharm. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Filings with the National Bank (10)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 03-06-2026 | 2026-00134040 | |
| 31-12-2024 | abbreviated format | 02-07-2025 | 2025-00221235 | |
| 31-12-2023 | abbreviated format | 01-07-2024 | 2024-00187342 | |
| 31-12-2022 | abbreviated format | 03-07-2023 | 2023-00188668 | |
| 31-12-2021 | abbreviated format | 29-06-2022 | 2022-20105895 | |
| 31-12-2020 | abbreviated format | 07-07-2021 | 2021-32200380 | |
| 31-12-2019 | abbreviated format | 29-07-2020 | 2020-35200480 | |
| 31-12-2018 | abbreviated format | 29-08-2019 | 2019-53300582 | |
| 31-12-2017 | abbreviated format | 03-07-2018 | 2018-26500367 | |
| 31-12-2016 | abbreviated format | 31-08-2017 | 2017-52200100 |
Board & ownership
Directors
Directors
2 directors, last change in 2024
WALLER Ivana
Current
Director (not named in the articles) · since 27-04-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 03-06-2026
Mirna Šenjug Novak
Current
Director · since 23-11-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 03-06-2026
Owners and capital
Capital transactions
Capital over time
- 16-06-2023 Converted to unavailable equity · €18,688.88
Mandate history
4 people, 2 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| WALLER Ivana |
|
| Mirna Šenjug Novak |
|
| Martina Okun Šola |
|
| Gordana Greguri iak |
|
Network & group
Optimapharm shares no director with another company.
Companies at the same address
5 other companies- BTW-EENHEID LEMMENS Registered office · since 2026 1041402787
- Hotel Facility Concepts Belgium Registered office · since 2023 1000489870
- BUSINESSCLUB ZWAARVELD HAMME Registered office · since 2008 0808337028
- aternio finance Registered office · since 2000 0456045401
- Fidulemco AD Registered office · since 1984 0426166926
Connections & network
2 current directorsThe network starts from the directors of Optimapharm. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
03-06
abbreviated format · 58 days before the deadline
2025
31-12
Financial
Highest result from 2018 to 2025net €92,091 ▲756%
The operating result of €126,444 and the net result of €92,091 are both a record.
02-07
abbreviated format · 29 days before the deadline
2024
01-07
abbreviated format · 30 days before the deadline
06-03
Gazette deed
Resignation: Martina Okun Šola (director)Appointment: Mirna Šenjug Novak (director) · Director discharge4 points ▸
Gazette deed
Resignation: Martina Okun Šola (director)
Appointment: Mirna Šenjug Novak (director) · Director discharge4 points ▸
- General meeting, 23-11-2023
- Director resignation, Martina Okun Šola
- Director discharge, Martina Okun Šola
- Director appointment, Mirna Šenjug Novak (director)
2023
03-07
abbreviated format · 28 days before the deadline
16-06
Gazette deed
Change of role: Martina Okun Šola, from manager to directorResignation: Gordana Greguri iak (director) · Appointment: WALLER Ivana (director) · Amendment of the articles20 points ▸
Gazette deed
Change of role: Martina Okun Šola, from manager to director
Resignation: Gordana Greguri iak (director) · Appointment: WALLER Ivana (director) · Amendment of the articles20 points ▸
- General meeting, “buitengewone algemene vergadering van de aandeelhouders” (deed in Dutch)
- Amendment of the articles, mentioned 2 times in the deed
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “statutair onbeschikbare eigen vermogensrekening, vormen en meerderheden statutenwijziging” (deed in Dutch)
- Other provision, “Artikel 7” (deed in Dutch)
- Other provision, “Artikel 9” (deed in Dutch)
- Other provision, “Artikel 12” (deed in Dutch)
- Other provision, “Artikel 20” (deed in Dutch)
- Other provision, “ALGEMENE MAATREGELEN, Titel VIII” (deed in Dutch)
- Other provision, “Artikel 26” (deed in Dutch)
- Other provision, “Artikel 27” (deed in Dutch)
- Other provision, “Artikel 28” (deed in Dutch)
- The act holds 8 more points.
2022
29-06
abbreviated format · 32 days before the deadline
2021
07-07
abbreviated format · 24 days before the deadline
2020
31-12
Financial
Back to profitnet €31,076
The net result is €31,076, after one loss-making year.
29-07
abbreviated format · 2 days before the deadline
2019
31-12
Financial
Weakest financial yearnet -€120,341
The net result drops to -€120,341, the lowest from 2018 to 2025. It recovers the following year.
Show earlier events
29-08
abbreviated format · 29 days late
2018
03-07
abbreviated format · 28 days before the deadline
2017
31-08
abbreviated format · 31 days late
2015
19-08
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
Optimapharm in Dutch
Enterprise number
0635.584.382
Legal form
Private limited company
Status
Active, normale toestand
Founded
17-08-2015
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 16-06-2023 (in Dutch)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest, bij enkel besluit bestuursorgaan, administratieve zetels, agentschappen, werkhuizen, stapelplaatsen en bijkantoren in België…”
deed of 16-06-2023 (in Dutch)Registered office and establishments
Registered office
Zwaarveld 41D, 9220 Hamme (Vl.), Belgium
Establishment unit
Optimapharm, Zwaarveld 41D, 9220 Hamme (Vl.) since 24-08-2015 · unit number 2.245.331.947
Activities
NACEBEL 2025VAT activities
86910
Medical imaging and medical laboratories main activity
70200
Business and other management consultancy
72109
Other research and development on natural sciences
73300
Public relations and communication consultancy
82100
Office administrative and support services
82990
Other business support services
Social security (RSZ) activities
82990
Other business support services main activity
Codes under NACEBEL 2008
VAT activities
86901
Human health activities main activity
70210
Activities of head offices; management consultancy activities
70220
Business consulting
72190
Scientific research and development
82110
Office administrative, office support and other business support activities
82990
Other business support services
Social security (RSZ) activities
82990
Other business support services main activity
Joint committee
200 Aanvullend Paritair Comité voor de bedienden annual accounts 2025
Invoicing and payment
VAT number
BE 0635.584.382
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Sites & property
Location
Buildings and parcels at the address
Ground area
2,493 m²
Building footprint
591 m²
Building volume
3,239 m³
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 42452C0148/00L000 | Flanders | 2,493 m² | 1 · 591 m² | 7.7 m · 2 |